Evelo Biosciences Company Description
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects.
It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis.
The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology.
Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 66 |
Contact Details
Address: 620 Memorial Drive Cambridge, Delaware 02139 United States | |
| Phone | 617 577 0300 |
| Website | evelobio.com |
Stock Details
| Ticker Symbol | EVLO |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US2997341035 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Craig R. Jalbert CIRA | President, Secretary, Principal Executive, Financial and Accounting Officer and Director |
| Dr. Chun Zhang Ph.D. | Chief Technical Operations and Quality Officer |